SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as rival Hims & Hers has halted its compounded weight-loss pill following legal action from NVO and increased FDA scrutiny on such alternatives, reinforcing NVO's market leadership. The community is actively discussing the implications of this development alongside Novo's promising oral Wegovy launch momentum and ongoing share buyback program.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz following impressive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, coupled with strong financial reporting. This has led the community to discuss "disease modifying" potential and widespread anticipation of a substantial market re-rating and short covering ahead of its investor day.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of Bysanti (milsaperidone) with New Chemical Entity status and patent protection until 2044, igniting community speculation about a significant short squeeze and potential buyout offers from larger pharmaceutical firms. Investors are weighing the drug's long-term revenue potential against ongoing concerns of market manipulation and potential dilution.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent CagriSema trial results fuel intense community speculation that VKTX's 'best-in-class' VK2735 obesity drug is now an even more attractive buyout or partnership target for major pharmaceutical companies like AbbVie, given its strong efficacy and tolerability in the rapidly expanding weight loss market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending high following robust earnings and an optimistic 2026 outlook, reinforcing its leadership in the GLP-1 market, especially as a key competitor provided a weaker forecast. The community is also keenly watching its pipeline diversification through recent acquisitions and the anticipated launch of its oral weight-loss therapy.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid fresh positive news including its Huntington's disease trial approval and strong international Elevidys sales, sparking community debate over the significant undervaluation of its commercial gene therapy franchise and deep RNA pipeline ahead of upcoming earnings, especially with notable short interest.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as a pivotal player in AI infrastructure, fueled by NVIDIA's strategic investment to develop AI-native 5G and 6G networks, positioning it as an AI Edge Computing leader. The community is buzzing about its significant growth potential and undervalued status ahead of forthcoming financial updates, despite some frustration over market volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is seeing intense discussion driven by renewed global tariff concerns after a recent ruling and subsequent policy changes, prompting a fierce debate among community members predicting either a sharp market correction or a swift V-shaped recovery amid broader geopolitical tensions and a notable crypto market downturn.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is experiencing significant community discussion following its top lawyer's resignation tied to Epstein documents, drawing sharp criticism regarding institutional integrity. Concurrently, CEO David Solomon's disclosed Bitcoin ownership is sparking broader conversations about the firm's evolving position in the cryptocurrency landscape.

Polygon

Polygon is trending due to its strategic pivot towards becoming a foundational layer for payments and Real-World Assets, underpinned by recent acquisitions and record network usage driving increased token burns. Despite community frustration that its price hasn't fully reflected these developments, many are actively accumulating Polygon, citing its strong fundamentals and perceived undervaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Banc of California, Inc. (NYSE:BANC) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Banc of California, Inc. (NYSE:BANC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the firm, MarketBeat reports. Two...

Hodges Capital Management Inc. Raises Position in Banc of California, Inc. $BANC

Hodges Capital Management Inc. increased its holdings in shares of Banc of California, Inc. (NYSE:BANC - Free Report) by 7.6% during the third quarter, according to the company in its most recent...

Public Sector Pension Investment Board Buys 74,926 Shares of Banc of California, Inc. $BANC

Public Sector Pension Investment Board grew its stake in Banc of California, Inc. (NYSE:BANC - Free Report) by 17.2% in the third quarter, according to the company in its most recent Form 13F filing...

Banc of California Appoints Chris Healy as Executive Director, Head of Payments

Banc of California, a wholly owned subsidiary of Banc of California, Inc. (NYSE: BANC), today announced the appointment of Chris Healy as Executive Director, Head of Payments, a strategic hire that...

Banc Of California Preferred Stock, Series A Goes Ex-Dividend Soon

On 2/19/26, Banc Of California Inc's 7.75% Dep Shares Rate Reset Non-Cumul Preferred Stock, Series A (Symbol: BANC.PRF) will trade ex-dividend, for its quarterly dividend of $0.4845, payable on...

Banc of California (NYSE:BANC) Share Price Passes Above 200 Day Moving Average - Time to Sell?

Banc of California (NYSE:BANC) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why...

Banc of California, Inc. (NYSE:BANC) Plans Dividend Increase - $0.12 Per Share

Banc of California, Inc. (NYSE:BANC) declared a quarterly dividend on Thursday, February 5th. Stockholders of record on Monday, March 16th will be given a dividend of 0.12 per share by the bank on...

Banc of California, Inc. Increases Quarterly Common Stock Dividend 20% to $0.12 Per Share

Banc of California, Inc. (the Company) (NYSE: BANC) announced today that its Board of Directors declared a quarterly cash dividend of $0.12 per share on its outstanding common stock, representing a...

Banc of California (NYSE:BANC) Sees Unusually-High Trading Volume - What's Next?

Banc of California (NYSE:BANC) Sees Large Volume Increase - What's Next...

Y Intercept Hong Kong Ltd Purchases 53,506 Shares of Banc of California, Inc. $BANC

Y Intercept Hong Kong Ltd boosted its position in Banc of California, Inc. (NYSE:BANC - Free Report) by 308.4% in the third quarter, according to its most recent disclosure with the Securities and...

Banc of California, Inc. is a holding company engaged in the provision of commercial banking services. It offers personal banking, business and commercial banking, real estate banking, and private banking. The company was founded in 1941 and is headquartered in Los Angeles, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.38	--	--	N/A
Q4 '25	$0.37	$0.42	13.96%	BEAT
Q3 '25	$0.32	$0.38	17.06%	BEAT
Q2 '25	$0.26	$0.12	-54.22%	MISSED
Q1 '25	$0.23	$0.26	11.38%	BEAT

BANC
Banc of California Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BANC News

BANCBanc of California Inc